Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AB001 |
| Synonyms | |
| Therapy Description |
AB001 is a PSMA-targeting ligand conjugated to 212Pb, which may deliver radiation to PSMA-expressing tumor cells, leading to tumor growth inhibition (PMID: 34062920, PMID: 40081958). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AB001 | 212Pb-NG001|AB 001|AB-001 | AB001 is a PSMA-targeting ligand conjugated to 212Pb, which may deliver radiation to PSMA-expressing tumor cells, leading to tumor growth inhibition (PMID: 34062920, PMID: 40081958). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07214961 | Phase I | AB001 | Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (ARTISAN) | Recruiting | USA | 0 |